Antiamphetamine effects following inhibition of tyrosine hydroxylase.
D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001362:Avoidance Learning; D001522:Behavior, Animal; D002746:Chlorpromazine / Q000494:pharmacology; D004295:Dihydroxyphenylalanine / Q000494:pharmacology; D004798:Enzymes / Q000494:pharmacology*; D066298:In Vitro Techniques; D008297:Male; D008781:Methyltyrosines / Q000494:pharmacology; D051379:Mice; D006899:Mixed Function Oxygenases / Q000494:pharmacology*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism / Q000494:pharmacology; D010634:Phenobarbital / Q000494:pharmacology; D051381:Rats; D014363:Tryptamines / Q000494:pharmacology; D014443:Tyrosine / Q000494:pharmacology*
D004798:Enzymes; D008781:Methyltyrosines; D008996:Monoamine Oxidase Inhibitors; D014363:Tryptamines; D014443:Tyrosine; D004295:Dihydroxyphenylalanine; D000661:Amphetamine; D006899:Mixed Function Oxygenases; D001058:Apomorphine; D002746:Chlorpromazine; D009638:Norepinephrine; D010634:Phenobarbital